LENZ Therapeutics registers resale of 1,022,809 shares by selling securityholders; company gets no proceeds

Filed April 9, 2025 · ~1 min read

Key Changes

• high

  The prospectus covers resale of 1,022,809 shares issued in a PIPE financing; all shares are sold by existing securityholders.

  The Offering verify on EDGAR →
• high

  LENZ will not receive any proceeds from these sales; all proceeds go to the selling securityholders.

  The Offering verify on EDGAR →
• medium

  Last reported sale price on Nasdaq was $18.32 on April 8, 2025.

  The Offering verify on EDGAR →